Trial Profile
Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Imidafenacin; Propiverine; Solifenacin; Tolterodine
- Indications Overactive bladder
- Focus Adverse reactions
- Acronyms MILAI II STUDY
- Sponsors Astellas Pharma
- 04 Oct 2016 Status changed from active, no longer recruiting to completed.
- 08 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2014 New trial record